Clinical Trial Update: A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 study of GSK2118436 (dabrafenib) in patients with BRAF-mutant metastatic melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• GSK2118436 (dabrafenib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2014-06-02